Montefiore Einstein Joins National Trial Exploring Non-Surgical Options for Stage Zero Breast Cancer
Montefiore Einstein Comprehensive Cancer Center in New York is participating in the national RECAST clinical trial, which is testing whether some patients with stage zero breast cancer (DCIS) can be treated effectively with medication and close monitoring, potentially avoiding surgery…
New York, NY, October 7, 2026 — Montefiore Einstein Comprehensive Cancer Center in New York has announced its participation in the national RECAST clinical trial. This significant research initiative aims to evaluate alternative treatment strategies for patients diagnosed with stage zero breast cancer, also known as ductal carcinoma in situ (DCIS).
The RECAST trial is exploring whether a subset of DCIS patients can achieve effective management through medication and rigorous monitoring, potentially offering an alternative to surgical intervention. Traditionally, surgery has been a primary treatment option for DCIS. However, this trial seeks to determine if less invasive methods can yield comparable outcomes for certain individuals, especially when the disease shows no signs of progression.
Ductal carcinoma in situ (DCIS) is considered the earliest form of breast cancer. It is characterized by the presence of abnormal cells within the milk ducts, but these cells have not spread to surrounding breast tissue. While DCIS is non-invasive, it is recognized as a precursor to invasive breast cancer, and its treatment aims to prevent this progression.
The participation of Montefiore Einstein signifies a commitment to advancing breast cancer care by investigating approaches that could potentially reduce the need for surgery. This could lead to fewer side effects and a different patient experience for those diagnosed with this early-stage condition. The specifics of the medication regimen and the frequency of monitoring within the RECAST trial were not detailed in the provided information.
Information regarding the exact timeline for patient enrollment, the total number of participating centers beyond Montefiore Einstein, or the expected duration of the trial was not immediately available. Further details on the trial’s protocol and its potential impact on standard treatment guidelines are anticipated as the research progresses.
Story summarized from the original created by By Marina Samuel on www.bxtimes.com, see more information here.
